Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.

Shimizu T, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW, Smith LS, Gunn S, Smetzer L, Mays TA, Kaiser B, Wick MJ, Alvarez C, Cavazos A, Mangold GL, Patnaik A.

Clin Cancer Res. 2012 Apr 15;18(8):2316-25. doi: 10.1158/1078-0432.CCR-11-2381. Epub 2012 Jan 19.

2.

Preclinical antitumor activity and pharmacokinetics of methyl-2-benzimidazolecarbamate (FB642).

Hao D, Rizzo JD, Stringer S, Moore RV, Marty J, Dexter DL, Mangold GL, Camden JB, Von Hoff DD, Weitman SD.

Invest New Drugs. 2002 Aug;20(3):261-70.

PMID:
12201489
3.

Antitumor activity and toxicity of novel nitroheterocyclic phosphoramidates.

Borch RF, Liu J, Joswig C, Baggs RB, Dexter DL, Mangold GL.

J Med Chem. 2001 Jan 4;44(1):74-7.

PMID:
11141090
4.

Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S.

MacDonald JR, Muscoplat CC, Dexter DL, Mangold GL, Chen SF, Kelner MJ, McMorris TC, Von Hoff DD.

Cancer Res. 1997 Jan 15;57(2):279-83.

5.

Inhibition of breast cancer cell growth in vitro by a tyrosine kinase inhibitor.

Reddy KB, Mangold GL, Tandon AK, Yoneda T, Mundy GR, Zilberstein A, Osborne CK.

Cancer Res. 1992 Jul 1;52(13):3636-41.

Supplemental Content

Loading ...
Support Center